Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression

(MedPage Today) -- Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes, but the SGLT2 inhibitor...